Absci Corp
No SEC Form 4 filings for $ABSI in the last 30 days.
See all $ABSI insider activity →Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ABSI (Absci Corp). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent ABSI coverage spans earnings, market movers and sector analysis.
Move likely driven by broader biotech rally.
AI‑based approach offers differentiation but remains pre‑clinical; stock rally reflects speculative interest.
Earnings miss and sizable financing may pressure the stock short-term but extend runway.
AMD’s disclosed ownership may validate Absci’s AI compute consumption narrative and attract incremental investor attention.
The earnings miss is the immediate driver of repricing, with investors likely shifting focus from early Phase 1 signals to financial runway and next clinical milestones.
AlphAI scores every news story that mentions ABSI with an AI model for sentiment and relevance, and aggregates insider trades from Absci Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.
2 min readVeradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.
2 min readAbsci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.
3 min readAdvanced Micro Devices (AMD) filed its first 13F, revealing a $1.31 billion portfolio with six positions. Top holdings include SpaceX, Absci (ABSI), Sanmina (SANM), Nutanix (NTNX), and Quantum Computing (QUBT). AMD's Q2 revenue surged 50.1% YoY to $11.536 billion, with data center revenue doubling. AMD expects Q3 revenue of $13 billion, citing strong AI demand.
7 min readAbsci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.
3 min readAbsci Corp (ABSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly
6 min readAnthropic is reportedly targeting an IPO in September or early October 2026, according to the Wall Street Journal. In investor meetings, it said it plans to expand healthcare and biology AI use cases. The article highlights potential AI-biotech beneficiaries, citing results and guidance for Absci, Recursion, Schrodinger, Twist Bioscience, and Tempus AI, including Tempus Q2 revenue of $382.49M and raised FY guidance to $1.595 to $1.605B.
6 min readSzela Mary T purchased 12,900 shares of Absci Corp (ABSI) at $11.54 ($0.15M total) on 2026-06-30.
1 min readAbsci Corp. (NASDAQ:ABSI) shares rose premarket Wednesday after HC Wainwright upgraded its outlook, raising the price target from $8.00 to $16.00 and keeping a buy rating. The stock closed at $7.41 and opened at $9.51. Other analysts set targets from $11 to $15. The move follows positive interim Phase 1 ABS-201 data and a $100 million underwritten offering.
3 min readAbsci Corp (ABSI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d139233dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Execution Version ABSCI CORPORATION 13,495,277 Shares of Common Stock Underwriting Agreement June 24, 2026 Jefferies LLC J.P. Morgan Securities LLC TD Securities (USA) LLC Guggenheim Securities, LLC As Representatives of the sev
2 min read
